Paratek Pharmaceuticals, Inc. acquires OptiNose, Inc. (2025)

Deal facts

Buyer: Paratek Pharmaceuticals, Inc.
Target: OptiNose, Inc.
Deal value: Not disclosed
Announced: 20 March 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

21 May 2025CompletedClosed
Paratek Pharmaceuticals, Inc. completes acquisition of OptiNose, Inc.
Introductory Note. On May 21, 2025 (the “ Closing Date ”), OptiNose, Inc., a Delaware corporation (“ OptiNose ” or the “ Company ”), completed the previously announced merger of Orca Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”) and a wholly owned subsidiary of Paratek Pharmaceuticals, Inc., a Delaware corporation (“ Parent ”), with and into the Company (the “ Merger ”), with the Compa
Source

OpinionExit Mode editorial

The acquisition of OptiNose by Paratek Pharmaceuticals, announced on 2025-03-20 and now completed, offers a clear case study in how strategic buyers structure deals when uncertainty looms. Both parties are US based, operating within the healthcare sector, and the transaction relies on a mix of cash and earn-out provisions. We see this structure as a direct response to the valuation gap that often stalls life science deals. The buyer likely sought to limit upfront exposure while the seller needed a mechanism to capture future value if their assets perform as expected. This is not a simple cash-for-shares swap. It is a negotiated truce between differing views on worth.

For the SME founder reading this, the presence of an earn-out is a critical signal. It means the buyer does not fully trust the current financial projections or believes significant commercial risk remains. In the US healthcare landscape, this often points to regulatory hurdles, clinical trial outcomes, or market access challenges that have not yet been resolved. The deal mechanics here force the seller to stay engaged post-close to unlock the full price. This shifts the dynamic from a clean exit to a continued performance obligation. The founder must understand that the headline value is not the final value. The cash component provides immediate liquidity, but the earn-out portion is contingent on hitting specific targets that the buyer will define and monitor closely.

We note that the deal status is listed as completed, which implies the initial regulatory and commercial conditions were satisfied. However, the earn-out structure introduces a new phase of scrutiny. For founders in similar positions, the risk lies in the potential for disputes over how those targets are measured or achieved. The buyer controls the operational levers that determine success, creating an inherent conflict of interest. This is a standard commercial mechanism in strategic acquisitions, yet it remains a frequent source of friction. The founder must weigh the certainty of the cash payment against the speculative nature of the deferred consideration.

The immediate action for any founder considering a similar path is to demand a written definition of the earn-out triggers before signing any term sheet. Do not accept vague language regarding "commercial milestones" or "regulatory approvals". Specify the exact metrics, the timeline, and the governance structure for measuring performance. If the buyer refuses to clarify these terms, the deal is not worth the risk.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from Paratek Pharmaceuticals, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history